Berlin – South Korean pharmaceutical firm Yuyu Pharma’s Bemfola Prefilled Pen (polytropin alfa), a fertility treatment, is facing increased scrutiny following reports of previously unreported side effects, including ovarian hyperstimulation syndrome (OHSS) and syncope (fainting). The South Korean Ministry of Food and Drug Safety (MFDS) is currently reviewing data from a domestic post-market surveillance study … Read more
Source link